Takemura N, Saiura A, Koga R, Yamamoto J, Yamaguchi T
1 Department of Gastroenterological Surgery, Cancer Institute Ariake Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
2 Department of Surgery, National Defense Medical College, Saitama, Japan.
Scand J Surg. 2017 Sep;106(3):224-229. doi: 10.1177/1457496916669630. Epub 2016 Sep 20.
Relatively little is known about the risk factors and treatments for postpancreatectomy hepatic steatosis.
The records of patients who underwent pancreaticoduodenectomy or total pancreatectomy between 2005 and 2010 and were followed up by periodic imaging were reviewed retrospectively. Risk factors and treatment for postpancreatectomy hepatic steatosis were analyzed.
A total of 253 patients were included in the analysis, including 137 males and 116 females, of median (5, 95 percentile) age 67 (47, 81) years. Of these 253 patients, 75 (29.6%) developed postpancreatectomy hepatic steatosis. Multivariable logistic regression analysis showed that female gender ( p = 0.005; odds ratio: 2.387; 95% confidence interval: 1.293-4.386), body mass index > 22.5 kg/m ( p = 0.007; odds ratio: 2.330; 95% confidence interval: 1.261-4.307), operative duration > 540 min ( p = 0.018; odds ratio: 2.286; 95% confidence interval: 1.153-4.533), and delayed gastric emptying ( p < 0.001; odds ratio: 4.598; 95% confidence interval: 1.979-10.678) were independent risk factors associated with postpancreatectomy hepatic steatosis. Treatment consisted of maintenance- or high-dose digestive enzyme replacement therapy. Of patients without obvious tumor recurrence after 6 months, 12 of 15 treated with high dose and only 6 of 35 treated with maintenance-dose digestive enzyme replacement therapy showed improvements in postpancreatectomy hepatic steatosis ( p = 0.006).
Female gender, obesity, longer operative time, and occurrence of delayed gastric emptying are risk factors for postpancreatectomy hepatic steatosis. High-dose digestive enzyme replacement therapy may improve postpancreatectomy hepatic steatosis.
关于胰十二指肠切除术后肝脂肪变性的危险因素及治疗方法,人们了解相对较少。
回顾性分析2005年至2010年间接受胰十二指肠切除术或全胰切除术并接受定期影像学随访的患者记录。分析胰十二指肠切除术后肝脂肪变性的危险因素及治疗方法。
共有253例患者纳入分析,其中男性137例,女性116例,年龄中位数(第5、95百分位数)为67(47,81)岁。在这253例患者中,75例(29.6%)发生了胰十二指肠切除术后肝脂肪变性。多因素logistic回归分析显示,女性(p = 0.005;比值比:2.387;95%置信区间:1.293 - 4.386)、体重指数>22.5 kg/m²(p = 0.007;比值比:2.330;95%置信区间:1.261 - 4.307)、手术时间>540分钟(p = 0.018;比值比:2.286;95%置信区间:)以及胃排空延迟(p < 0.001;比值比:4.598;95%置信区间:1.979 - 10.678)是与胰十二指肠切除术后肝脂肪变性相关的独立危险因素。治疗包括维持剂量或高剂量消化酶替代疗法。在6个月后无明显肿瘤复发的患者中,接受高剂量治疗的15例中有12例、接受维持剂量消化酶替代疗法的35例中有6例胰十二指肠切除术后肝脂肪变性得到改善(p = 0.006)。
女性、肥胖、手术时间较长以及胃排空延迟的发生是胰十二指肠切除术后肝脂肪变性的危险因素。高剂量消化酶替代疗法可能改善胰十二指肠切除术后肝脂肪变性。